Suppliers and packagers for generic pharmaceutical drug: dextroamphetamine

dextroamphetamine

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401	NDA	Noven Therapeutics, LLC	68968-0205-3	30 POUCH in 1 CARTON (68968-0205-3) / 1 PATCH, EXTENDED RELEASE in 1 POUCH (68968-0205-1)	2023-05-15
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401	NDA	Noven Therapeutics, LLC	68968-0210-3	30 POUCH in 1 CARTON (68968-0210-3) / 1 PATCH, EXTENDED RELEASE in 1 POUCH (68968-0210-1)	2023-05-15
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401	NDA	Noven Therapeutics, LLC	68968-0215-3	30 POUCH in 1 CARTON (68968-0215-3) / 1 PATCH, EXTENDED RELEASE in 1 POUCH (68968-0215-1)	2023-05-15
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401	NDA	Noven Therapeutics, LLC	68968-0220-3	30 POUCH in 1 CARTON (68968-0220-3) / 1 PATCH, EXTENDED RELEASE in 1 POUCH (68968-0220-1)	2023-05-15

Dextroamphetamine API Suppliers and Key Market Dynamics

Last updated: February 19, 2026

This report identifies current and prospective suppliers of dextroamphetamine active pharmaceutical ingredient (API), analyzes their manufacturing capacities, and assesses geopolitical and regulatory factors impacting the global supply chain. The market is characterized by a limited number of established manufacturers, stringent regulatory oversight, and increasing demand driven by ADHD diagnoses.

Who are the Primary Dextroamphetamine API Manufacturers?

The production of dextroamphetamine API is concentrated among a select group of companies globally. These manufacturers operate under strict regulatory controls enforced by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

• Mallinckrodt Pharmaceuticals: A significant producer of dextroamphetamine sulfate API. The company has a long history of supplying controlled substances for pharmaceutical use.
• Kemira Oyj: While primarily known for industrial chemicals, Kemira has a specialty chemicals division that has historically been involved in the synthesis of pharmaceutical intermediates, including those relevant to amphetamine derivatives. Specific current involvement in dextroamphetamine API requires direct verification.
• Noramco Inc.: A subsidiary of Johnson & Johnson, Noramco is a leading U.S.-based manufacturer of controlled substance APIs, including amphetamine products. They possess substantial manufacturing capacity and adhere to rigorous compliance standards.
• WeylChem GmbH: A German fine chemicals manufacturer with capabilities in complex organic synthesis. Their product portfolio includes intermediates and APIs. Direct confirmation of current dextroamphetamine API production is necessary.
• Actavis Group (now part of Teva Pharmaceutical Industries): Teva, through its various acquisitions including Actavis, is a major global pharmaceutical player. While Teva has extensive API manufacturing operations, specific details regarding their dextroamphetamine API production volume and current status are typically proprietary.

What is the Global Manufacturing Capacity for Dextroamphetamine API?

Precise global manufacturing capacity figures for dextroamphetamine API are not publicly disclosed by manufacturers due to proprietary and security concerns. However, an assessment can be made based on reported market share, regulatory filings, and observed production trends.

• U.S. Dependence: The United States is a primary consumer of dextroamphetamine products and relies heavily on a limited number of domestic API manufacturers, such as Noramco and Mallinckrodt, to meet demand.
• Quota Systems: The Drug Enforcement Administration (DEA) in the U.S. imposes annual aggregate production quotas on controlled substances, including amphetamines. These quotas directly limit the total amount of dextroamphetamine API that can be legally manufactured within the U.S. annually. For 2023, the aggregate quota for amphetamine and its salts (which includes dextroamphetamine) was set at 18,500 kg [1]. This quota is a critical determinant of available API supply.
• International Sourcing: While some API may be imported, the regulatory hurdles and supply chain security considerations for Schedule II controlled substances often favor domestic or regional production for major markets.
• Capacity vs. Utilization: Manufacturers possess installed capacity that can exceed current quota allocations. However, production is constrained by these legal limits. The ability to rapidly scale up is therefore dependent on regulatory approval and quota adjustments.

How Do Regulatory Frameworks Impact Dextroamphetamine Supply?

The production, distribution, and sale of dextroamphetamine are governed by stringent international and national regulations due to its classification as a controlled substance.

• DEA Quotas (U.S.): The U.S. DEA regulates the manufacture, distribution, and possession of controlled substances through a quota system. Manufacturers must apply for and receive specific quotas to produce amphetamines, including dextroamphetamine. These quotas are reviewed annually and can be adjusted based on estimated medical, scientific, research, and industrial needs, as well as to prevent diversion [1]. Fluctuations in quota allocation directly affect the available supply of API.
• FDA Oversight (U.S.): The FDA regulates the safety, efficacy, and manufacturing quality of all pharmaceutical products, including those containing dextroamphetamine. Facilities must comply with Current Good Manufacturing Practices (cGMP). Inspections and audits are routine.
• International Narcotics Control Board (INCB): The INCB monitors the implementation of UN drug control treaties and assesses global licit requirements for narcotic drugs and psychotropic substances. This influences national estimates and import/export controls for controlled substances.
• EMA and National Agencies (Europe): In Europe, the European Medicines Agency (EMA) and national competent authorities regulate pharmaceutical manufacturing and supply. Marketing authorizations require demonstration of API quality and compliance with GMP.
• Supply Chain Security and Diversion Prevention: Regulatory bodies mandate robust security measures to prevent the diversion of dextroamphetamine API and finished products to illicit markets. This includes secure storage, transportation, and detailed record-keeping. These requirements add to the operational costs and complexity for manufacturers.

What are the Geopolitical and Supply Chain Risks for Dextroamphetamine API?

The concentrated nature of dextroamphetamine API manufacturing, coupled with regulatory complexities, exposes the supply chain to several risks.

• Limited Manufacturer Base: A small number of primary manufacturers means that disruptions at any single facility, whether due to operational issues, regulatory actions, or natural disasters, can have a significant impact on global supply.
• Geographic Concentration: If a large portion of API production is concentrated in a single country or region, geopolitical instability, trade disputes, or new protectionist policies in that area can disrupt supply. For instance, reliance on a few key international suppliers could be vulnerable to trade embargos or export restrictions.
• Raw Material Sourcing: The synthesis of dextroamphetamine involves precursor chemicals. Disruptions in the supply of these precursors, which may originate from different global sources, can also impact API production.
• Regulatory Changes: Unforeseen changes in DEA quota allocations, FDA enforcement priorities, or international drug control policies can rapidly alter the supply landscape. For example, a sudden reduction in a manufacturer's quota could lead to API shortages.
• Demand Volatility: While ADHD diagnoses are increasing, shifts in prescribing patterns or the introduction of new therapeutic alternatives could lead to demand fluctuations that are challenging for API manufacturers to quickly adjust to, especially given the rigidity of quota systems.

How is the Dextroamphetamine Market Evolving?

The market for dextroamphetamine API is undergoing several shifts driven by clinical, regulatory, and market forces.

• Increased ADHD Diagnoses: Global trends show a sustained increase in the diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) across pediatric and adult populations. This directly translates to higher demand for stimulant medications like dextroamphetamine.
• Extended-Release Formulations: A significant portion of the market has transitioned to extended-release (ER) formulations of dextroamphetamine. This requires more complex API characterization and manufacturing processes to ensure consistent drug release profiles.
• Generic Competition: While innovator products exist, the market for dextroamphetamine medications is largely supplied by generic manufacturers. This necessitates cost-effective API sourcing for these companies.
• Manufacturing Audits and Quality: Increased scrutiny on API quality and manufacturing practices by regulatory bodies, particularly post-pandemic, means manufacturers must maintain impeccable cGMP compliance and robust quality management systems. Any lapse can lead to production halts or import alerts.
• Potential for New Entrants (Limited): The high barrier to entry for controlled substance API manufacturing, including significant capital investment, rigorous regulatory approval processes, and the need for specialized security, makes it challenging for new companies to enter the dextroamphetamine API market. Existing players often have established relationships and scaled operations that are difficult to replicate.

Dextroamphetamine API Supplier Comparison

Supplier	Primary Product Form(s)	Primary Market Focus	Key Attributes	Potential Risks
Noramco Inc.	Dextroamphetamine Sulfate	North America	Significant U.S. capacity, strong cGMP compliance, established controlled substance manufacturer	Dependent on DEA quotas, potential for regulatory enforcement actions.
Mallinckrodt	Dextroamphetamine Sulfate	Global	Long-standing presence, broad controlled substance portfolio.	Financial restructuring, ongoing litigation impacting operations.
Kemira Oyj	Intermediates (Potential)	Global	Broad chemical synthesis capabilities, potential for upstream intermediates.	Direct dextroamphetamine API production status requires verification, market segment focus.
WeylChem GmbH	Intermediates (Potential)	Global	Fine chemical expertise, European base.	Specific dextroamphetamine API production requires confirmation, niche market presence.
Teva Pharmaceutical Industries (via Actavis acquisition)	Various	Global	Extensive global API manufacturing network, broad therapeutic areas.	Proprietary data on specific dextroamphetamine API capacity and allocation.

Note: This table provides a general overview. Specific production details and current capabilities are often proprietary. Direct engagement with suppliers is recommended for detailed assessment.

Key Takeaways

• The global dextroamphetamine API market is characterized by a limited number of qualified manufacturers, with Noramco Inc. and Mallinckrodt Pharmaceuticals being prominent U.S.-based suppliers.
• DEA aggregate production quotas in the U.S. are a critical constraint on API availability, directly limiting the total annual volume that can be legally manufactured.
• Stringent regulatory oversight by agencies like the FDA and DEA, coupled with international controls, creates high barriers to entry and necessitates robust compliance and security measures for all suppliers.
• Supply chain risks are elevated due to the concentrated nature of manufacturing, potential geopolitical factors affecting precursor sourcing, and the sensitive nature of controlled substance regulation.
• Growing demand for ADHD treatments is a primary market driver, while the shift towards extended-release formulations requires specialized API manufacturing capabilities.

Frequently Asked Questions

1. What is the current U.S. DEA aggregate production quota for dextroamphetamine? The 2023 U.S. DEA aggregate production quota for amphetamine and its salts, which includes dextroamphetamine, was set at 18,500 kg [1]. This quota is subject to annual review and adjustment.

2. Are there any new dextroamphetamine API manufacturers likely to enter the market in the near future? The entry of new manufacturers is improbable due to the significant capital investment, specialized technical expertise, stringent regulatory hurdles, and robust security requirements associated with producing Schedule II controlled substances.

3. How does FDA cGMP compliance impact dextroamphetamine API supply? FDA Current Good Manufacturing Practices (cGMP) compliance is mandatory for all API manufacturers supplying the U.S. market. Adherence ensures product quality, safety, and consistency. Non-compliance can lead to import alerts, production halts, and significant supply disruptions.

4. What are the main precursor chemicals for dextroamphetamine synthesis, and are they subject to supply chain risks? Key precursors can include phenyl-2-propanone (P2P) and related compounds. The sourcing and control of these chemicals are also subject to strict national and international regulations to prevent diversion for illicit synthesis, potentially impacting their availability for legitimate pharmaceutical manufacturing.

5. What is the typical lead time for securing a supply agreement for dextroamphetamine API? Lead times can vary significantly, but typically range from 6 to 18 months. This accounts for supplier qualification, quality audits, contract negotiation, and the establishment of secure logistical pathways, especially for controlled substances.

Citations

[1] U.S. Drug Enforcement Administration. (2022). 2023 Aggregate Production Quotas for Schedule I and II Controlled Substances; Establishment of Aggregate Production Quotas for 2023. Federal Register, 87(209), 68540-68564.